Use of Injectable Platelet Rich Fibrin in Lichen Planus
Status:
Completed
Trial end date:
2019-09-02
Target enrollment:
Participant gender:
Summary
Platelet Rich Fibrine (PRF), which promotes wound healing by supporting angiogenesis,
immunity and epithelial proliferation phases. over a decade has since past since PRF was
developed and many clinicians now point to the potential use of a liquid version of PRF. a
liquid injectable-platelet-rich fibrin (i-PRF) was developed by modifying spin centrifugation
forces. At lower centrifugation speeds and by utilizing non-glass centrifugation tubes, the
fibrin coagulation could be slowed down at early time points thus generating an injectable
PRF. Much like traditional PRF, i-PRF contains an increase in leukocyte number and is further
able to stimulate growth factor release.
Lichen planus is a common chronic mucocutaneous inflammatory disorder which generally affect
s middle aged adults. Therapeutic methods including topical and systemic corticosteroids for
the treatment of oral lichen planus (OLP) are suggested. However, long
-term use of corticosteroids may be associated with local and systemic complications, and
moreover, some patients may not be responsive.
The investigators aimed to apply a treatment of autogenous origin (including no foreign
products), considering the side effects of our corticosteroids. The study was designed as a
split mouth.
The investigators planned to administer I-PRF to one side and intralesional corticosteroid
therapy to the other side at patients with bilateral atrophic / erosive oral lichen planus
lesions